A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Study sponsor: Axsome Therapeutics, Inc. · AXSM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-11-21Actual
Enrollment · participants408Actual
Source updated2026-08-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.